KE

Kimball Electronics, Inc. (KE) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This filing covers the quarterly period ended December 31, 2024 (Fiscal Q2 2025). Kimball Electronics, Inc. is a global provider of electronics manufacturing services (EMS) serving automotive, medical, and industrial markets. The company recently completed the divestiture of its GES business on July 31, 2024, and announced a plan to cease operations at its Tampa facility to streamline its global footprint.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 15% year-over-year for both the quarter and the six-month period.
  • Automotive: Down 4% (Q2) and 8% (YTD), impacted by the loss of a major program and lower demand in North America/Europe, partially offset by China demand.
  • Medical: Down 22% (Q2) and 17% (YTD), driven by an FDA recall at a major customer and program wind-downs.
  • Industrial: Down 29% (Q2) and 25% (YTD), largely due to the sale of the GES business and declines in smart metering.
• Profitability Compression: Gross margin declined to 6.6% from 8.2% due to lost absorption on lower revenue volumes. Operating income fell 50% for the quarter and 52% YTD.
• Restructuring Costs: The company recorded $4.7 million in restructuring expenses for the quarter and $7.0 million YTD. This includes $3.0 million related to the new Tampa facility closure plan announced in November 2024.
• Asset Divestiture: The company recognized a $1.3 million pre-tax gain on the disposal of the GES business in the first half of the fiscal year.
• Debt Restructuring: In December 2024, the company amended its primary credit facility to add a $100 million term loan maturing in 2029 and terminated a secondary 364-day facility.

Guidance, Outlook, and Risks

• Outlook: Management expects consolidated net sales to continue to lag compared to fiscal year 2024 through calendar year 2025. This is attributed to the loss of a major automotive program, the GES divestiture, and ongoing impacts from the medical customer recall.
• Restructuring: The Tampa facility closure is expected to be substantially completed by the end of fiscal year 2025. Total exit costs are estimated between $6.5 million and $8.5 million, with an additional $0.5 million to $1.0 million in restructuring charges expected for the remainder of the year.
• Liquidity: The company maintains a strong balance sheet with a current ratio of 2.3 and a debt-to-equity ratio of 0.4. Short-term liquidity (cash plus unused credit facilities) totaled $280.3 million.
• Capital Allocation: The company continues its stock repurchase program, having repurchased $5.9 million of stock in the first six months of fiscal 2025. Approximately $22.3 million remains available under the plan.
• Risks: Key risks include global economic conditions, supply chain constraints, foreign exchange fluctuations, and the ability to replace expiring customer programs with new business.

Investor Verification Checklist

• Customer Concentration: Verify the specific impact of the "major automotive program" loss and the "major medical customer" FDA recall on future revenue visibility.
• Tampa Closure Execution: Monitor the timeline and actual costs associated with the Tampa facility closure and the transfer of production to Mexico and Jasper, Indiana.
• Margin Recovery: Assess whether gross margins can stabilize or improve as the company aligns its cost structure with lower sales volumes.
• Open Orders: Note that open orders decreased 33% to $564 million; verify if this backlog is indicative of future sales trends given the contract nature of the business.
• Debt Covenants: Confirm continued compliance with the amended credit facility covenants, specifically the leverage ratio (max 3.0x) and interest coverage ratio (min 3.5x).